Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Panamol
- Development stage
- Phase 4
- Lead developer
- Beacons Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Panamol is a generic formulation of paracetamol (acetaminophen) manufactured and marketed by Beacons Pharmaceuticals. It is a small molecule analgesic and antipyretic drug indicated for the temporary relief of fever and minor aches and pains. Panamol works primarily by inhibiting cyclooxygenase (COX) enzymes within the central nervous system, which reduces prostaglandin synthesis. Additionally, it acts on the hypothalamic heat-regulating center to produce its antipyretic effect. It is approved as an over-the-counter medicine in Singapore and has been available in the market since 1991, primarily in a 500mg oral tablet form.
- Brand names
- Panamol
- Other names
- paracetamolacetaminophen
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Panamol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Panamol.